StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > New company post on LinkedIn and twitter

<< Previous

Bullboard Posts

Next >>

Comment by ompong12on Apr 22, 2021 10:16pm

95 Views

Post# 33053248

RE:RE:New company post on LinkedIn and twitter

I've been waiting for a video demo of Aristotle in 2 years now......i hsven't seen one!!!!....are we really taliing of real medical technology here? Or is just pure concept and base idea patterned to sentinel principle. Why tripp can't make a video demo of aristotle? Hopefully sz cone out with one

gojotv! wrote: StageZero has had a stroke of luck with Covid testing this year, and is due for another when doctors see the importance of kick-starting wide-ranging cancer screening to make up for the Covid shortfall.
Aristotle has been launched right on time and in the right places to get a world of disrupted oncology back on track!
As for Covid testing, it is sure to go on for at least a year, as travellers re-enter the testing market.
North American travellers move in two directions seasonally...
East-West (transoceanic) in the summer, where an insufficiency of vaccine will make testing menadatory, and...
North-South in the winter, where again, lags in vaccination campaigns in warmer climes will mean that testing will be required to cross borders. There's no way that poorer countries now being ravaged by Covid will allow pleasure travellers in without a test.
We may see a lull in the fall and another small one in the spring, (probably what Tripp was referring to) but otherwise, we can count on that revenue until Aristotle has been fully ramped up.
By then, the superiority of Aristotle as a diagnostic technology will be well accepted, as hundreds who wouldn't have detected their cancers otherwise make the case for its use.
To say nothing of the ease of use!
We're saving patients from time-consuming, invasive and often painful testing methods already in use.
Breast-flattening mammography?!
A camera-tube winding up one's entrails?! Days of fasting and enemas?! Are people animals?
The age of barbaric procedures is dead.
The cost/result benefits will soon be made clear!
It's smooth sailing ahead for StageZero!
As savvy investors and early adopters come into the market, our greasy, basement-dwelling bashers will leave it, and the share value will skyrocket. This feels exactly like PYR did in late 2019 when I bought my shares at $0.37!
Let's do that again!
GLTA!

LithLover wrote: Stage posted a link to the article below on their social media with this intro comment:

"Studies have shown an alarming drop in cancer screenings and more advanced cancer during the COVID-19 pandemic. Oncologists are urging Americans to get tested, read more on the national public awareness campaign from Cancer Health "

https://www.cancerhealth.com/article/oncologists-urge-americans-get-cancer-screenings-back-track